Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available. Therefore, we aimed to assess the predictive and prognostic value of pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartl, Thomas, Onoprienko, Arina, Hofstetter, Gerda, Müllauer, Leonhard, Poetsch, Nina, Fuereder, Thorsten, Kofler, Paul, Polterauer, Stephan, Grimm, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615494/
https://www.ncbi.nlm.nih.gov/pubmed/34827698
http://dx.doi.org/10.3390/biom11111700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615494/
https://www.ncbi.nlm.nih.gov/pubmed/34827698
http://dx.doi.org/10.3390/biom11111700

Ejemplares similares